Dybly Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $134K

  • Investors
  • 2

Dybly General Information


Developer of pharmaceuticals intended for inflammatory and fibrotic disease patients. The company manufactures several molecules with interesting activity and safety profiles backed by hypothesis-driven small molecule drug design with validation by empirical data, enabling patients with fibrotic diseases, blood cancer, and rheumatoid arthritis to get a better cure.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Industries
Drug Discovery
Corporate Office
  • Im Erasmushaus
  • Baeumleingasse 18
  • 4051 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dybly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 21-Oct-2020 $134K 00000 00000 Completed Generating Revenue
2. Angel (individual) 25-Feb-2008 00000 00000 00.000 Completed Startup
1. Angel (individual) 01-Dec-2006 Completed Startup
To view Dybly’s complete valuation and funding history, request access »

Dybly Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 19,444 $0.119843 $16.81 $16.81 1x $16.81 1.19%
To view Dybly’s complete cap table history, request access »

Dybly Patents

Dybly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090004121-A1 Combination of picotamide with nafronyl Inactive 28-Jun-2007 0000000000 0
US-20080293772-A1 Salts of picotamide Inactive 21-May-2007 0000000000 0

Dybly Executive Team (3)

Name Title Board Seat Contact Info
Rolf Jan Rutten Co-Founder
You’re viewing 1 of 3 executive team members. Get the full list »

Dybly Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioBac Angel Group Minority 000 0000 000000 0
Eva Capital Accelerator/Incubator Minority 000 0000 000000 0
To view Dybly’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »